Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to Blenrep’s return to the market.
The post GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH appeared first on MedCity News.
